# ğŸ“… Daily Report - 2025-12-07

> ä»Šæ—¥ç­›é€‰å‡º **38** æ¡å†…å®¹ï¼Œæ¥è‡ª **3** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡åˆ©ç”¨ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºå­å®«å†…è†œå¼‚ä½ç—‡ç—…ç¶çš„æ··åˆåˆ†å­èº«ä»½ã€çº¤æ¯›è¡¨å‹åŠå…ç–«ç‰¹å¾ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   **è‚¿ç˜¤å¾®ç¯å¢ƒä¸æ²»ç–—**ï¼šç ”ç©¶èƒ¶è´¨æ¯ç»†èƒç˜¤å¾®ç¯å¢ƒçš„ä»£è°¢ä¸å…ç–«è°ƒæ§ï¼Œä»¥åŠæŠ—CSF-1Rç–—æ³•è”åˆå…ç–«åŒ–ç–—å¯¹ä¸‰é˜´æ€§ä¹³è…ºç™Œçš„æ²»ç–—æ•ˆåº”ã€‚
*   **å…ç–«ç»†èƒåŠŸèƒ½ä¸è°ƒæ§**ï¼šæ¢ç´¢EOSåœ¨Tregç¨³æ€ä¸­çš„ä½œç”¨ï¼Œä»¥åŠIL-4ã€IL-13ã€IL-22åœ¨ç‰¹åº”æ€§çš®ç‚ä¸­çš„ä½œç”¨ã€‚
*   **å‘è‚²ä¸ç–¾ç—…**ï¼šè§£æäººèƒå„¿è‚ºã€å‘è‚²ä¸­çš„äººè„‘ä»¥åŠå„¿ç§‘AMLçš„å•ç»†èƒè½¬å½•ç»„å­¦ç‰¹å¾ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   **ç©ºé—´è½¬å½•ç»„å­¦**ï¼šåº”ç”¨äºå­å®«å†…è†œå¼‚ä½ç—‡å’Œäººèƒå„¿è‚ºç ”ç©¶ï¼Œå®ç°ç»„ç»‡å±‚é¢çš„åˆ†å­è§£æã€‚
*   **ç¨³å®šåŒä½ç´ ç¤ºè¸ª**ï¼šç»“åˆé«˜é€šé‡æµ‹åºï¼Œæ­ç¤ºèƒ¶è´¨æ¯ç»†èƒç˜¤å¾®ç¯å¢ƒçš„ä»£è°¢è°ƒæ§ã€‚

### ğŸ”¬ æœŸåˆŠæ–‡ç« 

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡æ­ç¤ºè‚¿ç˜¤èµ·å§‹å¹²ç»†èƒé€šè¿‡è°ƒæ§ä¸­æ€§ç²’ç»†èƒå¯å¡‘æ€§ï¼Œé‡å¡‘æŠ—è‚¿ç˜¤å…ç–«å¾®ç¯å¢ƒï¼Œä¸ºç™Œç—‡å…ç–«æ²»ç–—æä¾›æ–°é¶ç‚¹ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- é˜æ˜è‚¿ç˜¤èµ·å§‹å¹²ç»†èƒå¦‚ä½•é€šè¿‡å¾®è°ƒä¸­æ€§ç²’ç»†èƒå¯å¡‘æ€§ï¼Œå½±å“è‚¿ç˜¤å¾®ç¯å¢ƒçš„å…ç–«æŠ‘åˆ¶æˆ–æŠ—è‚¿ç˜¤æ´»æ€§ã€‚
- æ¢ç´¢æŠ— PDL1 + CD40 æ¿€åŠ¨å‰‚å…ç–«ç–—æ³•å¦‚ä½•è¯±å¯¼é³çŠ¶ç»†èƒç™Œï¼ˆSCCsï¼‰ä¸­ä¸­æ€§ç²’ç»†èƒçš„å¹²æ‰°ç´ ååº”ï¼Œæ¢å¤å…¶æŠ—è‚¿ç˜¤åŠŸèƒ½ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- æ•´åˆå•ç»†èƒ RNA æµ‹åºã€ç©ºé—´è½¬å½•ç»„å­¦å’Œé—ä¼ å­¦æ–¹æ³•ï¼Œå®ç°å¯¹è‚¿ç˜¤ç›¸å…³ä¸­æ€§ç²’ç»†èƒï¼ˆTANsï¼‰å¼‚è´¨æ€§å’ŒåŠŸèƒ½çš„æ·±åº¦è§£æã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
æ–°å‹ç©ºé—´è½¬å½•ç»„å­¦è´¨æ§å·¥å…·Spatial Touchstoneé—®ä¸–ï¼Œæå‡æ•°æ®è´¨é‡ä¸è·¨å¹³å°å¯æ¯”æ€§ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- åˆ©ç”¨å•ç»†èƒè½¬å½•ç»„å­¦ç»“åˆé—ä¼ æ¡å½¢ç æŠ€æœ¯ï¼Œè§£æé£Ÿç®¡ç™Œå‰ç—…å˜ä¸­ç»†èƒåŠ¨åŠ›å­¦ï¼Œæ¢ç´¢æ—©æœŸè¯Šæ–­ä¸æ²»ç–—æ–°é¶ç‚¹ã€‚
- å‘ç°ä¸€ç§æ–°å‹æŠ—è¡°è€è¯ç‰©èƒ½å»¶é•¿é…µæ¯å¯¿å‘½ï¼Œå¹¶æ­ç¤ºäº†ä¸ç”Ÿé•¿è°ƒæ§é€šè·¯åŠagmatinasesé…¶çš„å…³è”ã€‚
- å»ºç«‹PERlncDBå¹³å°ï¼Œé€šè¿‡RNAæµ‹åºå’Œè¡¨è§‚åŸºå› ç»„å­¦æ•°æ®ï¼Œæ·±å…¥ç ”ç©¶æ¤ç‰©é•¿é“¾éç¼–ç RNAçš„è¡¨è§‚é—ä¼ è°ƒæ§æœºåˆ¶ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- ç©ºé—´è½¬å½•ç»„å­¦æ•°æ®æ ‡å‡†åŒ–ä¸è´¨é‡æ§åˆ¶ã€‚
- ç»“åˆå¤šç§ç»„å­¦æ•°æ®ï¼ˆRNA-seq, è¡¨è§‚åŸºå› ç»„å­¦ï¼‰è§£æç”Ÿç‰©è¿‡ç¨‹ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (32æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE303150 ç©ºé—´è½¬å½•ç»„å­¦æ­ç¤ºå­å®«è…ºè‚Œç—‡ç—…å˜çš„æ··åˆåˆ†å­ç‰¹æ€§ã€çº¤æ¯›è¡¨å‹å’Œå…ç–«ç‰¹å¾**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€spatialã€spatial transcriptomicsã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributors : Alison Maclean ; Emily Johnson ; Corie Rushworth ; Christopher J Hill ; Eva Caamano-Gutierrez ; Dharani K HapangamaSeries Type : OtherOrganism : Homo sapiensAdenomyosis is a common gynaecological condition characterised by ectopic endometrial tissue within the myometrium, causing debilitating symptoms with limited treatment options. Despite its prevalence, the pathogenesis of adenomyosis remains poorly understood, hindering the development of targeted therapies for true disease modification rather than symptom management. The objective of this study was to elucidate the spatial transcriptomic profile of adenomyosis lesions with matched eutopic endometrial subregions, with a focus on specific cell types and tissue compartments. The study was designed to identify differentially expressed genes, functionally enriched pathways, and cell-cell communication networks within adenomyosis lesions compared to matched endometrial subregions, and to nominate potential drug targets for future therapeutic development. We show that adenomyosis lesions exhibit a distinct transcriptome intermediate between matched endometrium and myometrium, with enhanced epithelial ciliation and altered biological pathways. We reveal that lesion transcriptome is more like the endometrial basalis than the functionalis, displaying increased olfactory signalling, altered oxidative phosphorylation and ATP synthesis, and an altered immune microenvironment suggestive of chronic inflammation. In silico drug screening identified potential compounds that can reverse the adenomyosis lesion transcriptome. These findings provide insights into the molecular landscape of adenomyosis lesions and pave the way for developing novel, lesion-specific treatments that could potentially spare the eutopic endometrium and offer alternatives to hysterectomy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303150)

**2.** â­ **GSE310610 äººç±»èƒå„¿è‚ºçš„ç©ºé—´è½¬å½•ç»„å­¦**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šspatialã€spatial transcriptomicsã€transcriptomics
- ğŸ“ **æè¿°**ï¼šContributor : Bhattacharya SoumyaroopSeries Type : OtherOrganism : Homo sapiensSpatial transcriptomic profiles were generated using lung tissue sections obtained from twelve prenatal human lung samples ranging in gestational age from 13 â€“ 20 weeks, of which four were diagnosed with Trisomy 21, with defined hypoplasia.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310610)

**3.** **GSE283949 å›ºæœ‰å±‚è‚ é“å…ç–«ç»†èƒçš„å•ç»†èƒæµ‹åº**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€regex:intestin(e|al)
- ğŸ“ **æè¿°**ï¼šContributors : Wolfram Ruf ; Jens Posma ; Dilraj Kaur ; Thati MadhusudhanSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusA point mutation in GPCR-protease activated receptor-2 (F2RL1) renders PAR2 insensitive to FXa/Matriptase-dependent activation. We characterized the of impact of the PAR-2 G37I mutation on immune cell populations and gene expression in the gut.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283949)

**4.** **GSE312748 äººç±»è¡€æµ†æ ·åŸ¹å…»åŸºä¸­çš„ç¨³å®šåŒä½ç´ ç¤ºè¸ªæ­ç¤ºèƒ¶è´¨æ¯ç»†èƒç˜¤å¾®ç¯å¢ƒçš„ä»£è°¢å’Œå…ç–«è°ƒèŠ‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€metabolic
- ğŸ“ **æè¿°**ï¼šContributors : Milan R Savani ; Mohamad El Shami ; Bailey C Smith ; Samuel K McBrayerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensBackground In vivo stable isotope tracing is useful for natively surveying glioma metabolism but can be difficult to implement. Stable isotope tracing is tractable using in vitro glioma models, but most models lack nutrient conditions and cell populations relevant to human gliomas. This limits our ability to study glioma metabolism in the presence of an intact tumor microenvironment (TME) and immune-metabolic crosstalk. Methods We optimized an in vitro stable isotope tracing approach for human glioma explants and glioma stem-like cell (GSC) lines that integrates human plasma-like medium (HPLM). We performed 15N2-glutamine tracing in GSC monocultures and human IDH-wildtype glioblastoma explants and developed an analytical framework to evaluate microenvironment-dependent metabolic features that distinguish them. We also conducted spatial transcriptomics to assess transcriptional correlates to metabolic activities. Results Human plasma-like medium culture preserved glioma explant viability and stemness while unmasking metabolic and immune programs suppressed by conventional culture conditions. Stable isotope tracing in HPLM revealed TME-dependent and TME-independent features of tumor metabolism. Tissue explants recapitulated tumor cell-intrinsic metabolic activities, such as synthesis of immunomodulatory purines. Unlike GSC monocultures, tissue explants captured tumor cell-extrinsic activities associated with stromal cell metabolism, as exemplified by astrocytic guanosine diphosphate mannose production in heterocellular explants. Finally, glioma explants displayed tumor subtype-specific metabolic reprogramming, including robust pyrimidine degradation in mesenchymal cells. Conclusions We present a tractable approach to assess glioma metabolism in vitro under physiologic nutrient levels and in the presence of an intact TME. This platform opens new avenues to interrogate glioma metabolism and its interplay with the immune microenvironment.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312748)

**5.** **GSE292908 æŠ—CSF-1Rç–—æ³•è”åˆå…ç–«åŒ–ç–—åè°ƒé€‚åº”æ€§å…ç–«ååº”ä»¥æ¶ˆé™¤å¯Œå«å·¨å™¬ç»†èƒçš„ä¸‰é˜´æ€§ä¹³è…ºç™Œ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€macrophage
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusPatients diagnosed with metastatic triple negative breast cancer (mTNBC) have limited treatment options, are more prone to develop resistance and are associated with high mortality. A cold tumor immune microenvironment (TIME) characterized by low T cells and high tumor associated macrophages (TAMs) in mTNBC is associated with the failure of standard-of-care chemotherapy and immune checkpoint blockade (ICB) treatment. We demonstrate that the combination of immunostimulatory metronomic Cytoxan (CTX) coupled with anti-CSF-1R antibody targeted therapy (SNDX-ms6352) and anti-PD-1 (ICB), was highly effective against aggressive metastatic syngeneic Trp53 null TNBC genetically engineered mouse models (GEMMs) that present with high macrophage infiltration. Mechanistically, CSF-1R inhibition along with CTX disrupted the M-CSF/CSF-1R axis which upregulated IL-17, IL-15 and type II interferon and elevated B- and T cells. Addition of an anti-PD-1 maintenance dose was necessary to overcome de novo PD-L1 intra-tumoral heterogeneity (ITH) associated recurrence in lung and liver mTNBC.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292908)

**6.** **GSE303831 oHSVä»‹å¯¼çš„JAG1é˜»æ–­è¯±å¯¼èƒ¶è´¨ç˜¤è¡°è€ç›¸å…³åˆ†æ³Œè¡¨å‹ï¼Œä»è€Œå¢å¼ºå·¨å™¬ç»†èƒæ´»åŒ–å¹¶æé«˜å¯¹è¥¿å¦¥æ˜”å•æŠ—ä»‹å¯¼çš„è¡°è€ç»†èƒæ¸…é™¤çš„æ•æ„Ÿæ€§ II**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmacrophageã€glioma
- ğŸ“ **æè¿°**ï¼šContributors : Kimberly A Rivera-Caraballo ; Tae Jin Lee ; Arnoneel Sinha ; Marco Orecchioni ; Karina Vazquez-Arreguin ; Shilpa Sharma ; Kimya Jones ; Upasana Sahu ; Sara A Murphy ; Bangxing Hong ; Ravindra Kolhe ; Ashok Sharma ; Balveen KaurSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensOncolytic HSV-1 (oHSV) treatment induces Notch signaling and myelosuppression in the tumor microenvironment (TME) of preclinical models. In the clinic, upregulation of JAG1 gene expression was observed in recurrent high-grade glioma patients treated with CAN-3110. Since JAG1 is expressed on both glioma cells and tumor-associated macrophages (TAMs), and its expression correlated with a worse prognosis, we engineered a JAG1-antagonizing oHSV (OncoD-0J1) and interrogated its impact on the tumor and myeloid TME. OncoD-0J1 antagonized JAG1-mediated Notch signaling and had a significant therapeutic advantage in vivo, which relied on Notch signature in tumor cells. Kinome profiling revealed that OncoD-0J1 treatment suppressed CDK1, resulting in a G2/M cell cycle checkpoint as seen by cell cycle analysis. Cell cycle arrest led to senescence and correlated with increased reactive oxygen species, p62 accumulation, autophagosome accumulation, and senescence-associated beta-galactosidase activity. This resulted in increased production of inflammatory chemokines and DAMPs such as IL-1Î² and extracellular ATP. RNA sequencing of murine macrophages co-cultured with infected human tumor cells showed enrichment of chemotactic and pro-inflammatory pathways as well as increased Fc receptor activation following OncoD-0J1 infection. Single-cell RNA sequencing and flow cytometric analysis of F4/80+ cells isolated from infected tumors showed a shift from tumor-supporting TAMs to inflammatory macrophages upon OncoD-0J1 treatment. Senescent cells showed heightened EGFR activation as a mechanism to escape death, which created a unique vulnerability for cetuximab as a senolytic agent. Combination therapy reduced EGFR signaling and induced macrophage-mediated antibody-dependent cellular cytotoxicity, thereby increasing the anti-tumor therapeutic response of OncoD-0J1 as a monotherapy.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303831)

**7.** **GSE312113 æ€¥æ€§å»ç¥ç»æ”¯é…çš„è‚Œè‚‰ç»†èƒå¤–å›Šæ³¡é€šè¿‡é€†è¡Œä¿¡å·ä¼ å¯¼é‡å¡‘ç¥ç»å…ƒçº¿ç²’ä½“ä»£è°¢ï¼Œä»è€ŒæŒ½æ•‘å‘¨å›´ç¥ç»æŸä¼¤**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmetabolismã€Neuronal
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusPeripheral nerve injury causes muscle atrophy due to slow axonal regeneration, highlighting an unmet therapeutic need. Although neuromuscular interactions are classically viewed as unidirectionally nerve-dominated, we show that acutely denervated muscle (adMu) regulates nerve regeneration via a retrograde signaling pathway. adMu initiates a trans-tissue regulatory mechanism through extracellular vesicles (EVsadMu) that orchestrate neural energy homeostasis to accelerate regeneration. Functional profiling identifies IDH2 and CS as key metabolic enzymes within EVsadMu. Neurons treated with EVsadMu exhibit a 1.39-fold increase in NADPH/NADP+ ratio via IDH2, along with a 1.18- and 1.27-fold increase in NADH/NAD+ and FADH2/FAD ratios via CS, fueling the TCA cycle to enhance mitochondrial bioenergetics. This restores redox balance and energy supply, driving axonal regeneration. In sciatic nerve injury models, EVadMu-microneedle conduits significantly promote energy metabolism and functional recovery. Together, our findings position adMu as a metabolic signaling center enabling retrograde regulation for nerve regeneration, offering potential for clinical translation.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312113)

**8.** **GSE311272 SAFB1/SAFB2 æ•²é™¤æˆ– ERH æ•²é™¤å¯¹å°é¼  Baf3 ç»†èƒ miRNA è½¬å½•ç»„çš„å½±å“**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štranscriptome
- ğŸ“ **æè¿°**ï¼šContributors : Sebastian Herzog ; Aschenwald SimonSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Mus musculusMicroRNAs are small non-coding RNAs that mediate post-transcriptional silencing of most mammalian genes. They are generated in a multi-step process initiated by the Microprocessor, a protein complex composed of DROSHA and DGCR8. Recent studies have described the phenomenon of â€œcluster assistanceâ€, in which a prototypic primary miRNA hairpin can license the Microprocessor-mediated processing of a clustered suboptimal hairpin in cis. Mechanistic analyses led to the identification of two critical factors for this process, SAFB2 (scaffold attachment factor B2) and ERH (enhancer of rudimentary homolog), but it remains unclear to which extent these factors contribute to and are required for cluster assistance. Here, we have used a previously established dual fluorescence reporter system (doi: 10.1016/j.molcel.2020.05.011) to generate loss-of-function clones for SAFB2 and its closely related family member SAFB1 as well as for ERH.Our data indicate that loss of SAFB1/2 and of ERH results in overlapping, but not identical defects in primary miRNA biogenesis.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311272)

**9.** **GSE305409 å—œé…¸æ€§ç²’ç»†èƒç»´æŒ Treg ç¨³æ€ï¼Œå¹¶åœ¨å¾ªç¯èƒ¸è…º Treg çš„åŠŸèƒ½ä¸­å‘æŒ¥å…³é”®ä½œç”¨ [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Xuan Xie ; Asya Khleborodova ; Tovah E Markowitz ; Ethan M ShevachSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusEos, a member of the Ikaros family of transcription factors, is expressed by T regulatory cells (Tregs) and has been postulated to play a role in Treg suppression and maintenance of Treg stability. We demonstrate that expression of Eos was limited to a subpopulation of thymus-derived, activated Tregs and is undetectable in resting or activated T conventional cells (Tconvs). Eos associates with Helios, Foxp3 and Hdac1 and binds directly to the CD25 locus at a site identical to the Foxp3 binding site resulting in enhancement of CD25 expression. Studies in heterozygous female mice demonstrate that Eos is critical for Treg survival and activation. Eos+ Tregs also represent the major population of recirculating thymic Tregs, in which Eos plays a critical role in regulating their migration and suppression of Treg precursors in the thymus by competing for IL-2 and depleting MHC II from thymic dendritic cells (DCs).
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305409)

**10.** **GSE305408 Eos maintains Treg homeostasis and plays a critical role in the function of recirculating thymic Tregs [ChIP-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šChIP-seq
- ğŸ“ **æè¿°**ï¼šContributors : Xuan Xie ; Tovah E Markowitz ; Ethan M ShevachSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusEos, a member of the Ikaros family of transcription factors, is expressed by T regulatory cells (Tregs) and has been postulated to play a role in Treg suppression and maintenance of Treg stability. We demonstrate that expression of Eos was limited to a subpopulation of thymus-derived, activated Tregs and is undetectable in resting or activated T conventional cells (Tconvs). Eos associates with Helios, Foxp3 and Hdac1 and binds directly to the CD25 locus at a site identical to the Foxp3 binding site resulting in enhancement of CD25 expression. Studies in heterozygous female mice demonstrate that Eos is critical for Treg survival and activation. Eos+ Tregs also represent the major population of recirculating thymic Tregs, in which Eos plays a critical role in regulating their migration and suppression of Treg precursors in the thymus by competing for IL-2 and depleting MHC II from thymic dendritic cells (DCs).
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305408)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 22 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (1æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰

**1.** **è‚¿ç˜¤èµ·å§‹å¹²ç»†èƒé€šè¿‡å¾®è°ƒä¸­æ€§ç²’ç»†èƒçš„å¯å¡‘æ€§ï¼Œå¡‘é€ ä¿æŠ¤æ€§ç”Ÿæ€ä½**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤
- ğŸ“ **æè¿°**ï¼šSecret hovertext: è‚¿ç˜¤ç›¸å…³ä¸­æ€§ç²’ç»†èƒï¼ˆTANï¼‰çš„å¼‚è´¨æ€§å·²è¢«è®¤è¯†ï¼Œä½† TAN çš„ä¸åŒç»†èƒçŠ¶æ€å¦‚ä½•å‡ºç°ã€æ¼”åŒ–ã€åˆ†å¸ƒå¹¶å½±å“ç™Œç—‡å…ç–«æ²»ç–—ç–—æ•ˆä»éš¾ä»¥ç†è§£ã€‚é€šè¿‡å•ç»†èƒ RNA æµ‹åºã€ç©ºé—´è½¬å½•ç»„å­¦å’Œé—ä¼ ä½œï¼Œæˆ‘ä»¬è¡¨æ˜æŠ— PDL1 + CD40 æ¿€åŠ¨å‰‚å…ç–«ç–—æ³•èƒ½å¤Ÿè¯±å¯¼ TANs ä¸­çš„å¹²æ‰°ç´ ååº”ï¼Œä½¿å…¶åœ¨é³çŠ¶ç»†èƒç™Œï¼ˆSCCsï¼‰ä¸­æ¢å¤æŠ—è‚¿ç˜¤æ´»æ€§ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œä½äºè‚¿ç˜¤-åŸºè´¨ç•Œé¢çš„ TAN å¯ä»¥ä¿æŒå…¶å…ç–«æŠ‘åˆ¶çŠ¶æ€ã€‚é‡è¦çš„æ˜¯ï¼Œæˆ‘ä»¬åœ¨è‚¿ç˜¤-é—´è´¨ç•Œé¢è¯†åˆ«å‡ºä¸€ç»„ SOX2 é«˜è‚¿ç˜¤èµ·å§‹å¹²ç»†èƒï¼ˆtSCsï¼‰ï¼Œå®ƒä»¬ä¸Šè°ƒè„‚è‚ªé…¸å»é¥±å’Œé…¶ 1ï¼ˆFads1ï¼‰ç”ŸæˆèŠ±ç”Ÿå››çƒ¯é…¸ï¼ˆAAï¼‰ã€‚è¯¥ tSC ç‰¹å¼‚æ€§é€šè·¯å¢å¼º TAN ä¸­çš„å‰åˆ—è…ºç´  E2ï¼ˆPGE2ï¼‰ä¿¡å·ï¼Œä»è€Œç ´åå¹²æ‰°ç´ ååº”ï¼Œé˜»æ­¢ TANs ä¸­å¹²æ‰°ç´ è¯±å¯¼çš„æŠ—è‚¿ç˜¤åŠŸèƒ½ã€‚é€šè¿‡å¾®è°ƒä¸­æ€§ç²’ç»†èƒçš„å¯å¡‘æ€§ï¼ŒtSCs å¡‘é€ äº†ä¸­æ€§ç²’ç»†èƒçš„å¼‚è´¨æ€§ï¼Œå¡‘é€ äº†ä¸€ä¸ªä¿æŠ¤æ€§çš„å¾®ç”Ÿæ€ä½ï¼Œä»¥åœ¨å…ç–«æ²»ç–—ä¸­å­˜æ´»å¹¶æ¨åŠ¨ç™Œç—‡å¤å‘ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://m.x-mol.com/paper/1997050534773764096/t)


</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (5æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨5æ¡ï¼‰

**1.** â­ **Spatial Touchstone ä¸ºç©ºé—´è½¬å½•ç»„å­¦å¸¦æ¥è´¨é‡æ§åˆ¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šspatialã€spatial transcriptomicsã€transcriptomics
- ğŸ“ **æè¿°**ï¼šThe Spatial Touchstone dataset integrates RNA sequencing with imaging-based spatial transcriptomics, providing standardized metrics and tools to improve reproducibility and cross-platform comparisons across tissues....
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/spatial-touchstone-brings-quality-control-to-spatial-transcriptomics/)

**2.** **åˆ©ç”¨åŸºå› æ¡å½¢ç å’Œå•ç»†èƒè½¬å½•ç»„å­¦è§£è¯»ç»†èƒåŠ¨åŠ›å­¦**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsingle-cellã€transcriptomics
- ğŸ“ **æè¿°**ï¼šResearchers used RNA sequencing to trace progenitor cells in esophageal preneoplasia, identifying markers that could aid early detection and therapy of esophageal cancer....
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/deciphering-cell-dynamics-via-genetic-barcoding-and-single-cell-transcriptomics/)

**3.** **æ–°ä¸€ä»£æŠ—ç™Œè¯ç‰©å±•ç°å‡ºæƒŠäººçš„æŠ—è¡°è€åŠŸæ•ˆ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€aging
- ğŸ“ **æè¿°**ï¼šA next-generation drug tested in yeast was found to extend lifespan and slow aging by influencing a major growth-control pathway. Researchers also uncovered an unexpected role for agmatinases, enzymes that help keep this pathway in balance. Diet and gut microbes may affect aging more than expected because they produce the metabolites involved.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2025/12/251205054729.htm)

**4.** **PERlncDBâ€”â€”ç”¨äºæ¢ç´¢æ¤ç‰©é•¿é“¾éç¼–ç RNAè¡¨è§‚é—ä¼ è°ƒæ§çš„æ–°å¹³å°**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šepigenetic
- ğŸ“ **æè¿°**ï¼šResearchers used RNA sequencing and epigenomic data to map plant lncRNAs, creating PERlncDB, a platform for exploring epigenetic regulation and functional roles across 19 plant...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/perlncdb-new-platform-developed-to-explore-epigenetic-regulation-of-plant-long-non-coding-rnas/)

**5.** **é˜¿å°”èŒ¨æµ·é»˜ç—…è¡€æ¶²æ£€æµ‹ç»“æœå¯èƒ½å¯¹è‚¾è„æœ‰é—®é¢˜çš„äººäº§ç”Ÿè¯¯å¯¼ã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šAlzheimer
- ğŸ“ **æè¿°**ï¼šA large study found that people with impaired kidneys tend to have higher Alzheimerâ€™s biomarkers, yet they donâ€™t face a higher overall risk of dementia. For those who already have elevated biomarkers, kidney problems may speed up when symptoms appear. The findings show that kidney health can change how Alzheimerâ€™s blood tests are read. Doctors may need to consider both organs to get a clearer picture.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2025/12/251205045845.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| transcriptomics | 5 |
| immune | 4 |
| spatial | 3 |
| spatial transcriptomics | 3 |
| single-cell | 3 |
| transcriptome | 3 |
| leukemia | 3 |
| metabolic | 3 |
| RNA-seq | 2 |
| methylation | 2 |
| cancer | 2 |
| aging | 2 |
| macrophage | 2 |
| epigenetic | 1 |
| ChIP-seq | 1 |
| regex:intestin(e|al) | 1 |
| scRNA | 1 |
| RNAseq | 1 |
| Alzheimer | 1 |
| immunity | 1 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (22æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE302854 Differential Transcriptome Features of Peripheral Blood Mononuclear Cells in Pulmonary Sarcoidosis with and without Extrapulmonary Lesions](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302854)
- [GSE294931 Transcriptome analysis of Drosophila melanogaster intestines upon knockdown of Tachykinin (Tk), the GPCR GulpR (CG32547), and bruchpilot (brp)](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294931)
- [GSE291168 é«˜åˆ†è¾¨ç‡ HIV-1 m6A è¡¨è§‚è½¬å½•ç»„æ­ç¤ºäº†å‰ªæ¥ä¾èµ–æ€§ç”²åŸºåŒ–ç°‡å’Œç‹¬ç‰¹çš„ 2-LTR è½¬å½•æœ¬ä¿®é¥°](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291168)
- [GSE275038 åœ¨é¢„åä¸è‰¯çš„å„¿ç«¥ AML ä¸­å‘ç°çš„ç‰¹å®šé—´å……è´¨åŸºè´¨ç»†èƒäºšç¾¤æœ‰åˆ©äºç™½è¡€ç—…å¹²ç»†èƒåœ¨éª¨é«“ä¸­çš„æŒç»­å­˜åœ¨ [scRNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275038)
- [GSE237261 RBM15B è°ƒæ§ MLL é‡æ’ç™½è¡€ç—…çš„è¿›å±•](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237261)
- [GSE194370 å¯¹ç» KPCã€4662ã€LLC æˆ– C26 ç»†èƒæ¡ä»¶åŸ¹å…»åŸºå¤„ç† 3 å¤©å’Œ 5 å¤©åˆ†åŒ–çš„ C2C12 ç»†èƒè¿›è¡Œ RNA æµ‹åºã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE194370)
- [GSE312635 é¥®é£Ÿé™åˆ¶æœŸé—´ï¼Œæ¿€ç´ é‡å¡‘å…ç–«ç³»ç»Ÿç»´æŒç—…åŸä½“æ§åˆ¶å’Œå…¨èº«è¥å…»ç¨³æ€](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312635)
- [GSE312316 æ¯ä½“è¥¿å¼é¥®é£Ÿæ”¹å˜åº“æ™®å¼—ç»†èƒæ¯”ä¾‹ï¼Œå¯¼è‡´æˆå¹´åå†æ¬¡æ¥è§¦è¥¿å¼é¥®é£Ÿæ—¶å‡ºç°ä»£è°¢åŠŸèƒ½éšœç¢ç›¸å…³çš„è„‚è‚ªè‚ç–¾ç—…](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312316)
- [GSE310125 äººç±»å¤§è„‘å‘è‚²è¿‡ç¨‹ä¸­çš„å•ç»†èƒè½¬å½•ç»„åˆ†æï¼ˆå¦Šå¨ 13ã€15å’Œ19å‘¨ï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310125)
- [GSE299721 é‡åº¦å­ç—«å‰æœŸä¸è„å¸¦è¡€ç»†èƒæ¯”ä¾‹çš„æ˜¾è‘—DNAç”²åŸºåŒ–å·®å¼‚æ— å…³](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299721)
- [GSE298975 å‡é’æ¯èŒ LOV ç»“æ„åŸŸè›‹ç™½è°ƒæ§ç¯å¢ƒèƒè¿«è€å—æ€§ã€é“ç¨³æ€å’Œç»†èŒæ€§æ¯èç—…æ¯’åŠ›](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298975)
- [GSE296213 LINE-1åŸºå› åº§è½¬å½•ä¿ƒè¿›è‡´ç™ŒæŸ“è‰²è´¨ç»“æ„çš„å½¢æˆ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296213)
- [GSE294654 æ”¯æ¶ä¾èµ–æ€§ CASP1 é™åˆ¶ç™½è¡€ç—…ä¸­è¿‡åº¦çš„ç»†èƒå†…åœ¨ç‚ç—‡ä¿¡å·ä¼ å¯¼ [THP1]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294654)
- [GSE294653 æ”¯æ¶ä¾èµ–æ€§ CASP1 é™åˆ¶ç™½è¡€ç—…ä¸­è¿‡åº¦çš„ç»†èƒå†…åœ¨ç‚ç—‡ä¿¡å·ä¼ å¯¼ [MDSL]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294653)
- [GSE292848 IL-4ã€IL-13 å’Œ IL-22 åœ¨ç‰¹åº”æ€§çš®ç‚ä¸Šçš®å±éšœåŠŸèƒ½éšœç¢å’Œçš®è‚¤ç‚ç—‡ä¸­çš„ä¸åŒä½œç”¨](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292848)
- [GSE287039 å›´äº§æœŸå°é¼ èƒ¸è…ºhAPCçš„å•ç»†èƒè½¬å½•ç»„åˆ†æ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287039)
- [GSE291876 è‚¾è„å•æ ¸è½¬å½•ç»„å­¦åœ¨æ…¢æ€§è‚¾è„ç—…ä¸´åºŠå‰æ¨¡å‹ä¸­é‰´å®šå‡ºæ–°çš„æ²»ç–—é¶ç‚¹ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291876)
- [GSE312035 PM2.5æš´éœ²å¯¹ä¹³è…ºç™Œäºšå‹æ¶æ€§è¿›å±•çš„å½±å“æœºåˆ¶](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312035)
- [GSE311225 äººç±»é€ è¡€çš„åˆ†å­å’Œè¡¨å‹è“å›¾å°†å¢æ®–åº”æ¿€ä¸å¹²ç»†èƒè¡°è€è”ç³»èµ·æ¥ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311225)
- [GSE289319 é˜¿éœ‰ç´ ç”Ÿç‰©åˆæˆçš„ä»£è°¢å·¥ç¨‹ï¼šé€šè¿‡æ°§åŒ–è¿˜åŸä¼´ä¾£ä¼˜åŒ–å’Œé˜¿éœ‰ç´ Açš„ç»“æ„åˆ†ææ¨è¿›P450å‚¬åŒ–](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289319)
- [GSE285957 åŸºäºé«˜é€šé‡æµ‹åºçš„åˆ›ä¼¤æ€§å¢ç”Ÿæ€§ç»ç’ƒä½“è§†ç½‘è†œç—…å˜å…”æ¨¡å‹ä¸­å·®å¼‚è¡¨è¾¾åŸºå› å’ŒmicroRNAçš„ç­›é€‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285957)
- [GSE285439 RNA-Seqåˆ†ææ­ç¤ºäº†ä¸åŒèŒé¾„çš„ç»†å¶ç«¹ï¼ˆChimonocalamus delicatusï¼‰ä¸åŒéƒ¨ä½èœç±»åŒ–åˆç‰©çš„è¡¨è¾¾æƒ…å†µã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285439)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-12-06 21:33*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*